Is there a duty to recontact in light of new genetic technologies? A systematic review of the literature | Zendy

Ellen Otten | Zendy; Mirjam Plantinga | Zendy; Erwin Birnie | Zendy; Marian Verkerk | Zendy; Anneke Lucassen | Zendy; Adelita V. Ranchor | Zendy; Irene M. van Langen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Is there a duty to recontact in light of new genetic technologies? A systematic review of the literature

Author(s) -

Ellen Otten,

Mirjam Plantinga,

Erwin Birnie,

Marian Verkerk,

Anneke Lucassen,

Adelita V. Ranchor,

Irene M. van Langen

Publication year - 2014

Publication title -

genetics in medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.509

H-Index - 128

eISSN - 1530-0366

pISSN - 1098-3600

DOI - 10.1038/gim.2014.173

Subject(s) - duty , genetic testing , duty of care , systematic review , engineering ethics , value (mathematics) , empirical evidence , medicine , medline , genetic engineering , psychology , computer science , political science , biology , genetics , law , epistemology , philosophy , machine learning , gene , engineering

With rapid advances in genetic technologies, new genetic information becomes available much faster today than just a few years ago. This has raised questions about whether clinicians have a duty to recontact eligible patients when new genetic information becomes available and, if such duties exist, how they might be implemented in practice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research